Literature DB >> 3272827

The effect of synthetic iron chelators on bacterial growth in human serum.

J H Brock1, J Licéaga, G J Kontoghiorghes.   

Abstract

The effect of synthetic iron chelators of the 1-alkyl-3-hydroxy-2-methylpyrid-4-one class (the L1 series) and 1-hydroxypyrid-2-one (L4) on bacterial growth in human serum was compared with those of the plant iron chelators mimosine and maltol and of the microbial siderophore desferrioxamine. None of the synthetic chelators enhanced growth of 3 Gram-negative organisms (Yersinia enterocolitica, Escherichia coli and Pseudomonas aeruginosa); in some cases they were even inhibitory. L4 strongly stimulated growth of Staphylococcus epidermidis, but the L1 series had only a marginal effect. Maltol was mildly inhibitory to all 4 bacterial species, while mimosine enhanced the growth of S. epidermidis and Y. enterocolitica but had little effect on E. coli or P. aeruginosa. Desferrioxamine enhanced the growth of all except E. coli. These results suggest that the chelators of synthetic or plant origin may carry less risk of increasing susceptibility to bacterial infection in patients undergoing chelation therapy for iron overload than does desferrioxamine, the drug currently in clinical use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3272827     DOI: 10.1111/j.1574-6968.1988.tb02490.x

Source DB:  PubMed          Journal:  FEMS Microbiol Immunol        ISSN: 0920-8534


  12 in total

Review 1.  Targeting iron assimilation to develop new antibacterials.

Authors:  Timothy L Foley; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2012-07-19       Impact factor: 6.098

2.  Iron and Pseudomonas aeruginosa biofilm formation.

Authors:  Ehud Banin; Michael L Vasil; E Peter Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

3.  Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica.

Authors:  Biliana Lesic; Jeannine Foulon; Elisabeth Carniel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.

Authors:  George J Kontoghiorghes
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

5.  The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa.

Authors:  Amanda G Oglesby-Sherrouse; Louise Djapgne; Angela T Nguyen; Adriana I Vasil; Michael L Vasil
Journal:  Pathog Dis       Date:  2014-02-10       Impact factor: 3.166

6.  In vivo evidence of free radical generation in the mouse lung after exposure to Pseudomonas aeruginosa bacterium: an ESR spin-trapping investigation.

Authors:  Keizo Sato; Jean Corbett; Ronald P Mason; Maria B Kadiiska
Journal:  Free Radic Res       Date:  2012-03-16

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 9.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  Inhibitors of TonB function identified by a high-throughput screen for inhibitors of iron acquisition in uropathogenic Escherichia coli CFT073.

Authors:  Alejandra Yep; Thomas McQuade; Paul Kirchhoff; Martha Larsen; Harry L T Mobley
Journal:  MBio       Date:  2014-02-25       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.